RECURRENT PRIMARY AMYLOIDOSIS

Clinical trials for RECURRENT PRIMARY AMYLOIDOSIS explained in plain language.

Never miss a new study

Get alerted when new RECURRENT PRIMARY AMYLOIDOSIS trials appear

Sign up with your email to follow new studies for RECURRENT PRIMARY AMYLOIDOSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1 Completed 1

Early trial tests new drug cocktail for rare, debilitating protein disease

Disease control Ongoing

This early-stage study is testing the safety and best doses of a three-drug combination (daratumumab, ixazomib, and dexamethasone) for people with AL amyloidosis, a rare disease where abnormal proteins damage organs. The goal is to see if this combination can control the disease …

Matched conditions: RECURRENT PRIMARY AMYLOIDOSIS

Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control

Last updated Apr 02, 2026 02:11 UTC

RECURRENT PRIMARY AMYLOIDOSIS

Get alerted when new RECURRENT PRIMARY AMYLOIDOSIS trials appear

Early trial tests new drug cocktail for rare, debilitating protein disease